MIT researchers have developed a new type of spring-like device that uses a flexible element to help power biohybrid robots, reports Brian Heater for TechCrunch. “The muscle fiber/flexure system can be applied to various kinds of robots in different sizes,” Heater writes, adding that the researchers are, “focused on creating extremely small robots that could one day operate inside the body to perform minimally invasive procedures.”
Nature reporter Amanda Heidt speaks with postdoctoral researcher Tigist Tamir about her experience using generative AI with attention-deficit hyperactivity disorder. “Whether I’m reading, writing or just making to-do lists, it’s very difficult for me to figure out what I want to say. One thing that helps is to just do a brain dump and use AI to create a boiled-down version,” Tamir explains. She adds, “I feel fortunate that I’m in this era where these tools exist.”
NASA astronaut Christopher Williams PhD '12 shares his excitement over the upcoming solar eclipse with Space.com Elizabeth Howell, noting he is most excited that the celestial event will provide unique views of the sun’s outer atmosphere. Williams previously conducted radio astronomy research and helped build the Murchison Widefield Array in Australia during his time at MIT. "It was an incredible experience, because I got to both work on the cosmology and the science behind that,” recalls Williams.
MIT researchers have discovered a protein found in human sweat that holds antimicrobial properties and can “inhibit the growth of the bacteria that causes Lyme disease,” reports Matt Fortin for NENC. The team believes this “type of protein could be put into a topical cream to make something called ‘Lyme Block’ – like sunblock, but for preventing Lyme.” "Ideally what we would love to do is give people more control over their own risk," says Principal Research Scientist Michal Tal. "And really try to develop this into a possible preventative that you could put on repellant or sunblock to protect against other elements of the outdoors that you could also protect yourself against Lyme."
Prof. Katharina Ribbeck speaks with Christopher Intagliata of Scientific American’s “Science Quickly” podcast about her research exploring how mucus can treat and prevent disease. “The basic building blocks of mucus that give mucus its gooey nature are these threadlike molecules—they look like tiny bottlebrushes—that display lots and lots of sugar molecules on their backbone,” explains Ribbeck. “And these sugar molecules—we call them glycans—interact with molecules from the immune system and microbes directly. And the exact configuration and density of these sugar molecules is really important for health.”
Researchers from MIT and elsewhere have isolated a “protein in human sweat that protects against Lyme disease,” reports Matthew Rozsa for Salon. The researchers believe that if “properly harnessed the protein could form the basis of skin creams that either prevent the disease or treat especially persistent infections,” writes Rosza.
Researchers from MIT and elsewhere are studying how T-cell receptors recognize antigens, reports Michael T. Nietzel for Forbes. The team “hopes to develop antigen-specific immunotherapies which could also have treatment implications for infectious diseases and allergies,” writes Nietzel.
Christina “Chris” Birch PhD '15 is among NASA’s newest class of astronauts, reports Norah O’Donnell for CBS Evening News. “These new astronauts could one day be part of the team that brings the first woman and first person of color to the surface of the moon and beyond.”
Senior Lecturer Guadalupe Hayes-Mota writes for Forbes about the ways AI is reshaping drug development. “In the next three years, we can anticipate a more streamlined, efficient and cost-effective drug development process, ultimately leading to faster access to life-saving drugs for patients worldwide,” Hayes-Mota writes. “This is not just an evolution; it is a revolution in healthcare powered by the intelligence of machines.”
Prof. Feng Zhang has been named to STAT’s 2024 STATUS List, which highlights the leaders shaping the future of health and life sciences, reports Dialynn Dwyer for Boston.com. “Among the companies he’s co-founded is Editas Medicine, which as of late 2023 was now the official holder of patent rights to the CRISPR-Cas9 gene editing tool used in the sickle cell therapy Casgevy, and Aera Therapeutics, which in February 2023 raised $193 million in venture funding to develop protein nanoparticles as a way of delivering gene editing,” Dwyer writes.
Research scientist Beth Pollack speaks with the New York Times’ Pam Belluck about her work studying the mechanisms of long Covid-19 and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). “Experts said the study, which is the N.I.H’s first detailed look at ME/CFS, should be considered only one step in understanding the condition, its severity and potential remedies,” explains Belluck. “We must advance the field towards research on treatment,” says Pollack.
Omar Abudayyeh '12, PhD '18 and Jonathan Gootenberg '13 speak with Robert Weisman at The Boston Globe about their deep-rooted working relationship, which began as undergraduates at MIT and has gone on to include joint appointments at the McGovern and Broad Institutes and multiple startups. “Science is difficult, and it’s great to have someone to do it with,” said Gootenberg. “You got to work with people you enjoy hanging out with.”
MIT researchers have developed new technology that allows vaccines to be directly inserted into the lymph nodes to target two of the most common mutations in the KRAS gene, which cause roughly one third of all cancers, reports Jaimie Seaton for Scientific American. “The team modified the small vaccine components to include a fatty acid, which enables the vaccine to effectively hitch a ride on albumin, a common protein found throughout the body,” explains Seaton. “Albumin serves as a molecular shuttle bus, with pockets on its surface where fatty acids can bind to it.”
Graduate student Lauren “Ren” Ramlan programmed Doom, an iD software video game, to run on a display made from E.coli cells, reports Andrew Paul for Popular Science. For the project to work, “Ramlan first grew cells within a 32×48 1-bit well plate, then connected the makeshift screen to a controller capable of processing and translating binary code into the ‘addition or omission of a repressor controlling the fluorescence of the cells,’” writes Paul. “Basically, Ramlan swapped a traditional screen’s tiny light diodes for glowing bacterial cells."
Prof. Ron Weiss co-founded Strand Therapeutics, a biotech company developing mRNA therapies, reports Emily Mullin for Wired. “The notion is that genetic circuits can really have significant impact on safety and efficacy,” says Weiss. “This begins to really open up the door for creating therapies whose sophistication can match the underlying complexity of biology.”